尿路感染诊断的新技术
该文总结了2024年尿路感染诊断现状,指出传统依赖症状、尿常规和培养的方法在复杂病例中存在局限,低水平菌尿和苛养菌常被遗漏。文章综述了快速分子病原鉴定、二代测序和先进药敏试验等现有和新兴技术,并强调这些方法带来独特挑战,实施时需适应新概念以避免误诊和过度治疗。
要点
- 传统尿培养易漏检低水平菌尿和苛养菌,需新诊断方法。
- 快速分子鉴定、二代测序和先进药敏是新兴技术方向。
- 新技术应用需调整概念以避免误诊和过度治疗。
核心结论
- 传统尿路感染诊断方法存在局限,新兴技术有望改善但需谨慎应用以避免误诊和过度治疗。
研究设计与样本
- 本文为小型综述,总结2024年尿路感染诊断现状及当前和即将出现的技术。
主要发现
- 标准尿培养常忽略或完全遗漏低水平菌尿和苛养菌。
- 快速分子病原鉴定、二代测序和先进药敏试验是当前和即将出现的技术。
临床怎么用
- 临床应认识传统尿培养的局限,对复杂病例考虑新兴诊断技术。
- 实施新技术时需适应新概念以避免误诊和过度治疗。
局限性
- 新兴诊断方法代表独特挑战,需领域适应新概念。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Urinary tract infections (UTIs) impose a substantial burden on patient quality of life and urine testing accounts for the majority of workload in many clinical microbiology laboratories. Traditional UTI diagnosis relies on symptoms, urinalysis, and culture which are interpreted based on historical guidelines. This approach, while foundational, presents limitations, particularly in complex cases. Low-level bacteriuria and the presence of fastidious organisms are often overlooked or entirely missed in standard urine culture, stressing the need for novel diagnostic methods and technologies. This mini-review summarizes the existing state of UTI diagnostics in 2024 and covers current and upcoming technologies including rapid molecular-based pathogen identification, next-generation sequencing, and advanced antimicrobial susceptibility testing. However, these methods represent unique challenges, and as they are implemented, they will require the field to adapt to new concepts to avoid misdiagnosis and overtreatment.
引用
- Bermudez T, Schmitz JE, Boswell M, et al. Novel technologies for the diagnosis of urinary tract infections. J Clin Microbiol. 2025. PMID: 39760497. doi:10.1128/jcm.00306-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。